黄曲霉毒素高危区肝细胞癌患者微粒体环氧化物水解酶基因检测  

Detection of Microsomal Epoxide Hydrolase Gene on Hepatocellular Carcinoma Patients in a High Risk Area of Aflatoxin B_1

作　　者：韦义萍[1] 马韵[2] 邓卓霖[2] 

机构地区：[1]广西医科大学护理学院病理学教研室,广西南宁530021 [2]广西医科大学病理学教研室,广西南宁530021

出　　处：《肿瘤防治杂志》2003年第10期1009-1011,共3页China Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金 ( 3 9860 0 3 2 );广西教育厅重点资助课题基金 ( 98-2 -8)

摘　　要：目的 :探讨微粒体环氧化物水解酶 (microsomalepoxidehydrolase ,mEH)低活性基因型与肝细胞癌 (hepatocellularcarcinoma ,HCC)的相关性。方法 :应用PCR RFLP和PCR方法检测 5 2例HCC患者和5 6例健康成人中微粒体环氧化物水解酶及谷胱甘肽硫转移酶M1和T1基因型频率的分布。结果 :发现mEH第 3外显子 113纯合组氨酸型和第 4外显子 139纯合组氨酸型都是低活性基因型 ,在HCC组和对照组分别占 5 7 1% (30 /5 2 )、4 8 2 % (2 7/5 6 ) ,82 7% (4 3/5 2 )、73 2 % (4 1/5 6 ) ,两组比较差异无显著意义 ,P >0 0 5。然而 ,mEH低活性型联合谷胱甘肽硫转移酶 (glutathiones transferase ,GST)M1和T1基因缺失型 ,差异有显著意义 ,P <0 0 5。结论 :mEH处于低活性基因型可能是地区性易感HCC的原因之一 ,但单一种解毒酶不起决定作用 ,多种解毒酶联合作用 。Objective To seek the relationship between low activity genotype of microsomal epoxide hydrolase (mEH) and the hepatocellular carcinoma (HCC).Methods Polymerase chain reaction restriction fragment length polymorphism (PCR RFLP) and Polymerase chain reaction (PCR) technique were used to determine the frequency of mEH and GSTM1 and GSTT1 in 52 HCC patients and 56 non cancer controls.Results The findings are that the mEH homozygous histidin 113 of exon 3 and homozygous histidin 139 of exon 4 are low activity genotypes.There are 57 1%(30/52) in HCC patients vs 48 2%(27/56) in controls,and 82 7%(43/52) vs 73 2%(41/56) respectively.There is no significant difference between HCC patients and control groups, P >0 05).However,mEH of low activity genotypes in combination with Glutathione Transferase GSTM1 or GSTT1 null genotypes significantly, P <0 05.Conclusion The common expression of mEH low active genotype in the population may be one of the reason for susceptibility to HCC.However,a single detoxific enzyme is not determinative.A combination of several detoxific enzymes of abnormality is increase HCC risk.

关 键 词：黄曲霉毒素B1 副作用 癌 肝细胞 酶学 谷胱甘肽硫转移酶 基因型 环氧化物水解酶类 微粒体 

分 类 号：R735.7[医药卫生—肿瘤] R392.11[医药卫生—临床医学]